Stocktoria
Anika Therapeutics, Inc. ANIK
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 1985-05-16
Anika Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 56.6% | 63.4% | 68.3% | 64.3% | 56.1% |
| Operating margin | -9.8% | -4.3% | 0.7% | 3.2% | 1.8% |
| Net margin | -9.6% | -47.0% | -68.4% | -13.1% | 2.8% |
| FCF margin | 3.9% | -1.9% | -6.0% | -2.7% | 2.2% |
| Return on assets | -5.7% | -27.8% | -30.5% | -4.3% | 1.2% |
| Return on equity | -7.6% | -36.6% | -38.9% | -5.2% | 1.4% |
| Current ratio | 4.72 | 4.88 | 5.26 | 6.07 | 5.66 |
| Revenue growth | -5.9% | -0.7% | 6.1% | -23.0% | 13.3% |
Source: SEC EDGAR filings · CIK 0000898437 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.